Revenue Growth and Strategic Initiatives Drive Performance
Mumbai, January 31, 2025 – Jubilant Pharmova Limited (NSE: JUBLPHARMA, BSE: 530019) has announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The company reported steady growth in revenues while implementing key strategic initiatives to strengthen its market position.
Key Financial Highlights (Standalone)
Particulars
Q3 FY2025
Q2 FY2025
Q3 FY2024
9M FY2025
9M FY2024
Revenue from Operations (₹ mn)
1,960
1,657
1,752
5,284
5,789
Total Income (₹ mn)
2,144
2,095
1,942
6,101
6,322
Profit Before Tax (₹ mn)
87
166
(23)
141
2
Net Profit / (Loss) (₹ mn)
53
105
(24)
56
(9)
EPS (₹ per share)
0.33
0.66
(0.15)
0.35
(0.06)
Financial Performance:
Revenue from operations for the quarter stood at ₹1,960 million, a YoY increase of 11.9% from ₹1,752 million in Q3 FY2024.
Net profit rose to ₹53 million from a loss of ₹24 million in the same period last year, marking a turnaround in performance.
The company’s expenses increased slightly to ₹2,057 million from ₹1,965 million in Q3 FY2024, primarily driven by higher employee costs and depreciation.
Consolidated Financial Performance
Particulars
Q3 FY2025
Q2 FY2025
Q3 FY2024
9M FY2025
9M FY2024
Revenue from Operations (₹ mn)
18,217
17,523
16,771
53,057
49,443
Total Income (₹ mn)
18,309
17,740
17,129
53,506
49,986
Profit Before Tax (₹ mn)
1,305
1,444
1,010
7,746
2,242
Net Profit (₹ mn)
1,007
1,025
664
6,850
1,345
EPS (₹ per share)
6.37
6.47
4.22
43.28
8.56
Segment-Wise Performance
Radiopharma: Revenue stood at ₹8,412 million, up from ₹7,522 million in Q3 FY2024, reflecting strong demand.
Allergy Immunotherapy: Stable revenue at ₹1,740 million (vs. ₹1,724 million YoY).
Sterile Injectables: Revenue at ₹3,161 million, reflecting stable growth.
Generics: Revenue at ₹1,996 million, slightly lower YoY.
Proprietary Novel Drugs: No revenue contribution this quarter.
Key Corporate Announcements
The Roorkee facility in India, previously under a USFDA import alert, received a "Voluntary Action Indicated (VAI)" classification in April 2024, improving export potential.
The Salisbury, Maryland facility in the USA has ceased manufacturing operations, with outsourcing strategies in place.
The company sold its entire stake in SOFIE Biosciences Inc. for USD 143.20 million, using proceeds to reduce leverage and invest in strategic initiatives.
Provision for litigation settlements amounted to ₹283 million, and a ₹916 million expense was accrued for the Salisbury facility closure.
Management Commentary
Priyavrat Bhartia, Managing Director of Jubilant Pharmova, stated: "We are pleased with our performance this quarter, particularly the strong revenue growth in our Radiopharma and Allergy Immunotherapy businesses. Our strategic decisions, including the SOFIE Biosciences divestment and operational restructuring, will enhance profitability and strengthen our financial position. With the USFDA clearance for our Roorkee facility, we expect improved international sales momentum."
Outlook
Focus on expanding CDMO and sterile injectables business.
Strengthening compliance measures for USFDA-regulated sites.
Leveraging recent divestments to reduce debt and invest in high-growth areas.
Stock Market Reaction
The stock of Jubilant Pharmova traded flat post-results as investors assessed the impact of restructuring initiatives and regulatory improvements.